MannKind Corporation Stock Nasdaq
Stocks
US56400P2011
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| Market Cap | 1.21B 1.04B 987M 894M 1.68B 116B 1.69B 11.71B 4.5B 58.7B 4.54B 4.44B 186B | P/E 2026 * |
-20.6x | P/E 2027 * | -3,008x |
|---|---|---|---|---|---|
| Enterprise Value | 1.21B 1.04B 987M 894M 1.68B 116B 1.69B 11.71B 4.5B 58.7B 4.54B 4.44B 186B | EV / Sales 2026 * |
2.73x | EV / Sales 2027 * | 2.4x |
| Free-Float |
98.53% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : MannKind Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Castagna
CEO | Chief Executive Officer | 49 | 25/05/2017 |
| Director of Finance/CFO | 50 | 22/04/2024 | |
Ajay Ahuja
CTO | Chief Tech/Sci/R&D Officer | - | 29/09/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Ronald Consiglio
BRD | Director/Board Member | 82 | 01/10/2003 |
Michael Friedman
BRD | Director/Board Member | 82 | 01/12/2003 |
James Shannon
CHM | Chairman | 69 | 09/12/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.11% | -3.44% | +41.04% | +98.48% | 68.24B | |
| -0.23% | -6.42% | +30.19% | +76.15% | 62.23B | |
| +1.67% | +2.16% | -11.32% | +392.80% | 27.8B | |
| -1.05% | -7.30% | +25.00% | +12.31% | 24.86B | |
| +0.34% | -5.98% | -4.23% | -19.48% | 24.22B | |
| +0.43% | -4.78% | +18.26% | -20.61% | 19.36B | |
| -3.03% | -5.19% | +192.88% | +340.13% | 17.28B | |
| -1.94% | -6.36% | -7.05% | +516.16% | 14.46B | |
| -2.28% | -5.09% | +48.86% | +153.82% | 14.23B | |
| Average | -0.91% | -3.96% | +37.07% | +172.20% | 30.3B | |
| Weighted average by Cap. | -0.86% | -3.80% | +33.61% | +136.95% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 443M 382M 362M 328M 615M 42.37B 619M 4.29B 1.65B 21.53B 1.67B 1.63B 68.09B | 504M 435M 411M 373M 699M 48.15B 703M 4.88B 1.88B 24.47B 1.89B 1.85B 77.39B |
| Net income | -57.18M -49.31M -46.66M -42.27M -79.3M -5.46B -79.77M -554M -213M -2.78B -215M -210M -8.78B | 27.12K 23.39K 22.13K 20.05K 37.61K 2.59M 37.83K 263K 101K 1.32M 102K 99.6K 4.16M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
